Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Oct;66(4):717–719. doi: 10.1038/bjc.1992.344

Single agent high-dose cisplatin (200 mg m-2) treatment in ovarian carcinoma.

S Kehoe 1, C Redman 1, R Varma 1, J Buxton 1, D Luesley 1, G Blackledge 1, A Stanley 1
PMCID: PMC1977413  PMID: 1419613

Abstract

Twenty patients with epithelial ovarian carcinoma were treated with high-dose cisplatin 200mg m-2. Patients were to receive three cycles at 21 day intervals. Treatment was stopped if severe myelosuppression or any neurotoxicity occurred. Overall, eight (40%) of patients responded with a complete response in five (25%). Four of 16 (25%) previously treated patients responded. The median duration of response was 44 weeks (range 6-130). In patients previously treated there was a significant association (P < 0.002) between response and a remission free interval of 52 weeks or more from primary chemotherapy. Toxicity was assessable in 18 patients. Alopecia and nausea/vomiting were common. Myelosuppression was recorded in nine patients delaying planned administration in eight of 35 cycles. Five patients developed anaemia and six thrombocytopenia. Neurotoxicity affected seven patients and varying degrees of tinnitus six patients. Neurotoxicity and myelosuppression were indications for cessation of treatment in 8 patients receiving less than three cycles. Analysis revealed no significant association between toxicity and prior cisplatin exposure, age or the amount of high-dose cisplatin administered. This series reveals that it is possible to achieve good response rates using high-dose cisplatin without encountering debilitating neurotoxicity.

Full text

PDF
717

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Grunberg S. M., Sonka S., Stevenson L. L., Muggia F. M. Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol. 1989;25(1):62–64. doi: 10.1007/BF00694340. [DOI] [PubMed] [Google Scholar]
  2. Hainsworth J. D., Burnett L. S., Jones H. W., 3rd, Grosh W. W., Johnson D. H., Greco F. A. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma. J Clin Oncol. 1990 Mar;8(3):502–508. doi: 10.1200/JCO.1990.8.3.502. [DOI] [PubMed] [Google Scholar]
  3. Katz M. E., Schwartz P. E., Kapp D. S., Luikart S. Epithelial carcinoma of the ovary: current strategies. Ann Intern Med. 1981 Jul;95(1):98–111. doi: 10.7326/0003-4819-95-1-98. [DOI] [PubMed] [Google Scholar]
  4. Lambert H. E., Berry R. J. High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group. Br Med J (Clin Res Ed) 1985 Mar 23;290(6472):889–893. doi: 10.1136/bmj.290.6472.889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., Jones W., Almadrones L., Lewis J. L., Jr Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991 Mar;9(3):389–393. doi: 10.1200/JCO.1991.9.3.389. [DOI] [PubMed] [Google Scholar]
  6. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  7. Mollman J. E., Glover D. J., Hogan W. M., Furman R. E. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer. 1988 Jun 1;61(11):2192–2195. doi: 10.1002/1097-0142(19880601)61:11<2192::aid-cncr2820611110>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  8. Ozols R. F., Corden B. J., Jacob J., Wesley M. N., Ostchega Y., Young R. C. High-dose cisplatin in hypertonic saline. Ann Intern Med. 1984 Jan;100(1):19–24. doi: 10.7326/0003-4819-100-1-19. [DOI] [PubMed] [Google Scholar]
  9. Ozols R. F., Ostchega Y., Myers C. E., Young R. C. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol. 1985 Sep;3(9):1246–1250. doi: 10.1200/JCO.1985.3.9.1246. [DOI] [PubMed] [Google Scholar]
  10. Panici P. B., Greggi S., Scambia G., Di Roberto P., Iacobelli S., Mancuso S. High-dose (200 mg/m2) cisplatin-induced neurotoxicity in primary advanced ovarian cancer patients. Cancer Treat Rep. 1987 Jun;71(6):669–670. [PubMed] [Google Scholar]
  11. Pollera C. F., Marolla P., Nardi M., Ameglio F., Cozzo L., Bevere F. Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects. Cancer Chemother Pharmacol. 1988;21(1):61–64. doi: 10.1007/BF00262741. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES